Drugs / IAP0971
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06581419 | Dec 2024 → Aug 2029 expected | non-small cell lung carcinoma | SUNHO（China）BioPharmaceutical CO., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06223841 | Mar 2024 → Mar 2026 overdue | cancer | SUNHO（China）BioPharmaceutical CO., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06255964 | Feb → Oct 2024 overdue | urinary bladder cancer | SUNHO（China）BioPharmaceutical CO., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05396391 | Jun 2022 → May 2024 | cancer | SUNHO（China）BioPharmaceutical CO., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IAP0971 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06223841 ↗ |
| Route | Subcutaneous | “IAP0971 should be subcutaneous injected，q2w” NCT05396391 ↗ |